Related references
Note: Only part of the references are listed.PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
Pottayil G. Sasikumar et al.
COMMUNICATIONS BIOLOGY (2021)
P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
N. Patil et al.
Journal of Thoracic Oncology (2021)
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Sarah A. Weiss et al.
CLINICAL CANCER RESEARCH (2021)
Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI).
John M. Wrangle et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).
Oleh Kobziev et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings.
Roger B. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab +/- durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
TIM-3 restrains anti-tumour immunity by regulating inflammasome activation
Karen O. Dixon et al.
NATURE (2021)
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer
Zhenyu Ding et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Concepts for agonistic targeting of CD40 in immuno-oncology
David M. Richards et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Rationale for IL-15 superagonists in cancer immunotherapy
Karin M. Knudson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
Delvys Rodriguez-Abreu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.
John D. Powderly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tim-3 finds its place in the cancer immunotherapy landscape
Nandini Acharya et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
E. Felip et al.
ANNALS OF ONCOLOGY (2020)
Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
G. Giaccone et al.
ANNALS OF ONCOLOGY (2020)
Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy
Yuka Igarashi et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
Cinzia Solinas et al.
ESMO OPEN (2020)
Neoepitopes-based vaccines: challenges and perspectives
Vincent Alcazer et al.
EUROPEAN JOURNAL OF CANCER (2019)
Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
Xiaojie Yu et al.
MABS (2019)
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
Quentin Lecocq et al.
BIOMOLECULES (2019)
TIGIT signaling restores suppressor function of Th1 Tregs
Liliana E. Lucca et al.
JCI INSIGHT (2019)
Checkpoint inhibition: NK cells enter the scene
Ana Stojanovic et al.
NATURE IMMUNOLOGY (2018)
Targeting adenosine for cancer immunotherapy
Robert D. Leone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
Shan Xie et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer
Franz Villarroel-Espindola et al.
CLINICAL CANCER RESEARCH (2018)
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Gregory L. Beatty et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
Bertrand Allard et al.
IMMUNOLOGICAL REVIEWS (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Nicholas A. Manieri et al.
TRENDS IN IMMUNOLOGY (2017)
Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent
Yin Guo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Arabella Young et al.
CANCER CELL (2016)
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection
Todd C. Metzger et al.
CANCER RESEARCH (2016)
Emerging Opportunities and Challenges in Cancer Immunotherapy
Theresa L. Whiteside et al.
CLINICAL CANCER RESEARCH (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
VISTA Regulates the Development of Protective Antitumor Immunity
Isabelle Le Mercier et al.
CANCER RESEARCH (2014)
Allogeneic tumor cell vaccines The promise and limitations in clinical trials
Sanjay Srivatsan et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
J. Louise Lines et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Advances in targeting cell surface signalling molecules for immune modulation
Sheng Yao et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
Weiyi Peng et al.
ONCOIMMUNOLOGY (2013)
The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway
Akio Ohta et al.
FRONTIERS IN IMMUNOLOGY (2012)
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
Dallas B. Flies et al.
JOURNAL OF IMMUNOLOGY (2011)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
A2A Adenosine Receptor May Allow Expansion of T Cells Lacking Effector Functions in Extracellular Adenosine-Rich Microenvironments
Akio Ohta et al.
JOURNAL OF IMMUNOLOGY (2009)
Share Paper
